Galectin Therapeutics Inc. (GALT)
NASDAQ$1.695-0.06 (-3.41%)
Market Cap
$109.66M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
301 of 924
Rank in Industry
173 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GALT Insider Trading Activity
GALT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $95,930 | 14 | 74 |
Sells | $173,647 | 5 | 26 |
Related Transactions
| FREEMAN KEVIN D | director | 5 | $51,966 | 0 | $0 | $51,966 |
| Zordani Richard A. Jr. | director | 4 | $19,734 | 0 | $0 | $19,734 |
| ELDRED KARY | director | 3 | $13,301 | 0 | $0 | $13,301 |
| Shlevin Harold H. | director | 1 | $7,540 | 0 | $0 | $7,540 |
| LEWIS JOEL | President and CEO | 1 | $3,390 | 1 | $49,610 | $-46,220 |
| Jamil Khurram | Chief Medical Officer | 0 | $0 | 1 | $12,044 | $-12,044 |
| CALLICUTT JACK W | Chief Financial Officer | 0 | $0 | 1 | $35,492 | $-35,492 |
| CZIRR JAMES C | 10 percent owner | 0 | $0 | 2 | $76,500 | $-76,500 |
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which …
Insider Activity of Galectin Therapeutics Inc.
Over the last 12 months, insiders at Galectin Therapeutics Inc. have bought $95,930 and sold $173,647 worth of Galectin Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Galectin Therapeutics Inc. have bought $61,910 and sold $233,940 worth of stock each year.
Highest buying activity among insiders over the last 12 months: FREEMAN KEVIN D (director) — $51,966. Zordani Richard A. Jr. (director) — $19,734. ELDRED KARY (director) — $13,301.
The last purchase of 6,500 shares for transaction amount of $7,540 was made by Shlevin Harold H. (director) on 2024‑12‑30.
List of Insider Buy and Sell Transactions, Galectin Therapeutics Inc.
| 2024-12-30 | Shlevin Harold H. | director | 6,500 0.0105% | $1.16 | $7,540 | +18.18% | ||
| 2024-12-24 | ELDRED KARY | director | 13,469 0.0211% | $0.82 | $11,045 | +52.87% | ||
| 2024-12-24 | FREEMAN KEVIN D | director | 10,000 0.0155% | $0.81 | $8,134 | +52.87% | ||
| 2024-12-24 | Zordani Richard A. Jr. | director | 10,000 0.0156% | $0.82 | $8,164 | +52.87% | ||
| 2024-12-23 | Sale | LEWIS JOEL | President and CEO | 56,000 0.0895% | $0.89 | $49,610 | +43.80% | |
| 2024-12-23 | Sale | Jamil Khurram | Chief Medical Officer | 13,654 0.0217% | $0.88 | $12,044 | +43.80% | |
| 2024-12-23 | Sale | CALLICUTT JACK W | Chief Financial Officer | 40,000 0.064% | $0.89 | $35,492 | +43.80% | |
| 2024-10-23 | ELDRED KARY | director | 500 0.0008% | $2.60 | $1,300 | -38.95% | ||
| 2024-10-17 | FREEMAN KEVIN D | director | 1,300 0.0021% | $2.64 | $3,432 | -40.23% | ||
| 2024-10-16 | FREEMAN KEVIN D | director | 10,000 0.0164% | $2.70 | $27,000 | -39.45% | ||
| 2024-08-23 | Zordani Richard A. Jr. | director | 2,759 0.0044% | $2.30 | $6,346 | +5.63% | ||
| 2024-08-22 | Zordani Richard A. Jr. | director | 741 0.0012% | $2.30 | $1,704 | +5.41% | ||
| 2024-07-22 | ELDRED KARY | director | 400 0.0006% | $2.39 | $956 | -6.45% | ||
| 2024-06-20 | FREEMAN KEVIN D | director | 2,500 0.0037% | $2.38 | $5,950 | -3.93% | ||
| 2024-04-30 | Zordani Richard A. Jr. | director | 1,000 0.0016% | $3.52 | $3,520 | -29.63% | ||
| 2024-04-24 | LEWIS JOEL | President and CEO | 1,000 0.0016% | $3.39 | $3,390 | -24.32% | ||
| 2024-04-23 | Sale | CZIRR JAMES C | 10 percent owner | 3,677 0.0054% | $3.06 | $11,252 | -26.18% | |
| 2024-04-22 | Sale | CZIRR JAMES C | 10 percent owner | 21,323 0.0344% | $3.06 | $65,248 | -18.30% | |
| 2024-04-22 | FREEMAN KEVIN D | director | 2,500 0.0039% | $2.98 | $7,450 | -18.30% | ||
| 2024-01-16 | ELDRED KARY | director | 400 0.0008% | $2.39 | $956 | +37.36% |
Total: 236
*Gray background shows transactions not older than one year
Insider Historical Profitability
4.59%
| CZIRR JAMES C | 10 percent owner | 5922207 9.5047% | $10.42M | 3 | 30 | <0.0001% |
| LEWIS JOEL | President and CEO | 897012 1.4396% | $1.58M | 7 | 1 | <0.0001% |
| ELDRED KARY | director | 63682 0.1022% | $112,080.32 | 10 | 0 | +15.99% |
| FREEMAN KEVIN D | director | 44769 0.0719% | $78,793.44 | 29 | 0 | +0.09% |
| Zordani Richard A. Jr. | director | 42083 0.0675% | $74,066.08 | 7 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$12,784,645 | 193 | 20.49% | $110.08M | |
Galectin Therapeutics Inc. (GALT) | $22,597,521 | 91 | 4.59% | $109.66M |
$54,751,750 | 62 | -1.03% | $114.62M | |
$16,245,616 | 40 | 123.58% | $117.65M | |
$909,129 | 37 | 42.19% | $122.85M |
GALT Institutional Investors: Active Positions
| Increased Positions | 54 | +87.1% | 982,928 | +10.08% |
| Decreased Positions | 16 | -25.81% | 651,878 | -6.68% |
| New Positions | 19 | New | 412,885 | New |
| Sold Out Positions | 6 | Sold Out | 142,640 | Sold Out |
| Total Postitions | 100 | +61.29% | 10M | +3.39% |
GALT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $3,356.00 | 3.45% | 2.14M | +3,398 | +0.16% | 2024-12-31 |
| Blackrock, Inc. | $2,593.00 | 2.66% | 1.65M | +44,767 | +2.79% | 2024-12-31 |
| Osaic Holdings, Inc. | $1,856.00 | 1.91% | 1.18M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $1,367.00 | 1.4% | 870,589 | +8,047 | +0.93% | 2024-12-31 |
| Wealthspire Advisors, Llc | $625.00 | 0.64% | 398,374 | 0 | 0% | 2024-12-31 |
| Geneos Wealth Management Inc. | $611.00 | 0.63% | 388,935 | +36,000 | +10.2% | 2024-12-31 |
| Morgan Stanley | $455.00 | 0.47% | 290,084 | +44,004 | +17.88% | 2024-12-31 |
| State Street Corp | $451.00 | 0.46% | 287,514 | +36,500 | +14.54% | 2024-12-31 |
| Northern Trust Corp | $384.00 | 0.39% | 244,274 | +9,994 | +4.27% | 2024-12-31 |
| Atria Wealth Solutions, Inc. | $325.00 | 0.33% | 207,100 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.